osimertinib,gefitinib
Astrazeneca
['improve ', 'icon', 'nsclc', 'apple study', 'sclc']
the iconic apple study for the 1st time suggests that ct dna based management of patients with egfr mutated nsclc might improve pfs (+14% at 18mo) vs. ct-scan based management. ct dna clearance of egfrmut at 8 weeks highly predictive of tki benefit. #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.